Improved Commercial Deal Helps PTC Win English Funding For Duchenne Drug
Executive Summary
PTC Therapeutics has managed to convince England’s health technology assessment institute to reverse its recommendation against routine commissioning for Translarna.
You may also be interested in...
Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.
Requests For EMA PRIME Designation Fall But Improvements Are On The Way
While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.
UK’s NICE Slashes HTA Appraisal Time For Ngenla & Ofev Using New Approach
Ngenla and Ofev are the first two drugs to be evaluated using the health technology appraisal institute’s new proportionate approach – they were both appraised much faster than usual.